STOCK TITAN
  1. Home
  2. Sec-filings
  3. FHTX
  4. [Form 4] Foghorn Therapeutics Inc. Insider Trading Activity

Director Douglas G. Cole receives 28,000 Foghorn (NASDAQ: FHTX) stock options

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Foghorn Therapeutics director Douglas G. Cole received a compensation-related stock option grant. He was awarded options to buy 28,000 shares of common stock at an exercise price of $4.08 per share. These options vest in full on the first anniversary of the grant date, as long as he continues serving on the board. Following this grant, he holds 28,000 stock options, which are scheduled to expire on June 23, 2036.

Positive

  • None.

Negative

  • None.
Insider Cole Douglas G.
Role Director
Type Security Shares Price Value
Grant/Award Stock Options (Right to buy) 28,000 $4.08 $114K
Holdings After Transaction: Stock Options (Right to buy) — 28,000 shares (Direct)
Footnotes (1)
  1. F1. The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.
Options granted 28,000 options Stock options right to buy common stock
Exercise price $4.08 per share Option strike price for common stock
Expiration date June 23, 2036 Option term end date
Holdings after grant 28,000 derivative securities Total stock options held after this award
Stock Options (Right to buy) financial
"security_title: Stock Options (Right to buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
underlying security financial
"underlying_security_title: Common Stock"
vests in full financial
"The option vests in full on the first anniversary of the grant date"
board of directors financial
"subject to the reporting person's continued service on the board of directors"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

FAQ

What did Foghorn Therapeutics (FHTX) director Douglas G. Cole report in this Form 4?
Douglas G. Cole reported a grant of stock options for 28,000 shares of Foghorn Therapeutics common stock. The options were awarded as compensation and give him the right to buy shares at a fixed exercise price if vesting conditions are met.

How many FHTX shares are covered by the new stock options granted to Douglas G. Cole?
The stock option grant covers 28,000 shares of Foghorn Therapeutics common stock. These options represent potential future ownership if exercised, and the filing shows 28,000 derivative securities held by Cole after the transaction.

What is the exercise price of Douglas G. Cole’s Foghorn Therapeutics stock options?
The exercise price for Douglas G. Cole’s stock options is $4.08 per share. This means he can purchase Foghorn Therapeutics common stock at $4.08 if he exercises the options after they vest, regardless of the market price at that time.

When do Douglas G. Cole’s FHTX stock options vest and expire?
The options vest in full on the first anniversary of the grant date, subject to Cole’s continued service on the board. They are scheduled to expire on June 23, 2036, if not exercised before that expiration date.

Is Douglas G. Cole’s Form 4 transaction a stock purchase or a compensation grant?
The Form 4 shows a compensation-related grant of stock options, not an open-market stock purchase. The transaction is coded as an award acquisition, reflecting options granted to Cole as part of his service as a director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cole Douglas G.
(Last)(First)(Middle)
99 COOLIDGE AVENUE
STE 500
(Street)
WATERTOWN MASSACHUSETTS 02472
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Foghorn Therapeutics Inc. [ FHTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (Right to buy)$4.0806/24/2026A28,000 (1)06/23/2036Common Stock28,000$4.0828,000D
Explanation of Responses:
1. The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.
Remarks:
/s/ Michael LaCascia, Attorney-in-Fact for Douglas G. Cole06/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR